Motivations for Diverted Buprenorphine Use in a Multisite Qualitative Study

Abstract

Drawing on a multisite sample of 40 persons who sell, share, or use diverted buprenorphine to manage opioid use disorder, in this study we describe why individuals seek to obtain buprenorphine outside of formal treatment contexts, and between-site variation regarding their motives and means. Findings indicate that both the provision and purchase of diverted buprenorphine support user-defined risk minimization strategies to avoid withdrawal, reduce heroin use, and satiate opioid cravings in periods of lowered tolerance. We also found that a subset of the sample used buprenorphine recreationally, and that it functioned to extend or augment illicit drug use careers. Implications of the findings are discussed in light of federal and state drug control and treatment policies.

Keywords

opioid heroin buprenorphine treatment drug diversion

Get full access to this article

View all access options for this article.

References

Andrilla

C. H. A.

Moore

T. E.

Patterson

D. G.

Larson

E. H.

(2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. Journal of Rural Health, 35, 108–112.

Allen

Harocopos

(2016). Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma. Journal of Substance Abuse Treatment, 70, 81–86.

American Society of Addiction Medicine. (n.d.). Summary of the comprehensive addiction and recovery act. https://www.asam.org/advocacy/find-a-policy-statement/issues/opioids/summary-of-the-comprehensive-addiction-and-recovery-act#:~:text=Its%20provisions%20address%20the%20full,services%20and%20overdose%20reversal%20medications

Bazazi

A. R.

Yokell

J. J.

Rich

J. D.

Zaller

N. D.

(2011). Illicit use of buprenorphine-naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine, 5, 175–180.

Bretteville-Jensen

A. L.

Lillehagen

Gjersing

Andreas

J. B.

(2015). Illicit use of opioid substitution drugs: Prevalence, user characteristics, and the association with non-fatal overdoses. Drug and Alcohol Dependence, 147(1), 89–96.

Centers for Disease Control and Prevention. (2019). Vital statistics rapid release: Provisional drug overdose death counts. National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Chilcoat

H. D.

Amick

H. R.

Sherwood

M. R.

Dunn

K. E.

(2019). Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Journal of Substance Abuse Treatment, 104, 148–157.

Cicero

T. J.

Ellis

M. S.

Chilcoat

H. D.

(2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117–123.

Daniulaityte

Falck

Carlson

R. G.

(2012). Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug and Alcohol Dependence, 201–207.

10.

Daniulaityte

Nahhas

R. W.

Silverstein

Martins

Zaragoza

Moeller

Carlson

R. G.

(2019). Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis. Drug and Alcohol Dependence, 204, Article 107574.

11.

DEA Philadelphia Division. (2019). Bulletin: Drug-related overdose deaths in Pennsylvania, 2018 (No. DEA-PHL-BUL-132-19). Drug Enforcement Agency.

12.

Department of Health and Human Services. (2019, September 4). Trump Administration announces $1.8 billion in funding to states to continue combating opioid crisis. HHS Press Office. https://www.hhs.gov/about/news/2019/09/04/trump-administration-announces-1-8-billion-funding-states-combating-opioid.html

13.

Department of Health and Human Services. (2020, January). Geographic disparities affect access to buprenorphine services for opioid use disorder (No. OE-12-17-00240). https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf

14.

D’Onofrio

O’Connor

P. G.

Pantalon

M. V.

Chawarski

M. C.

Busch

S. H.

Owens

P. H.

… Fiellin

D. A.

(2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. The Journal of the American Medical Association, 313, 1636–1644.

15.

Farabee

Leukefeld

C. G.

Hays

(1998). Accessing drug-abuse treatment: Perceptions of out-of treatment injectors. Journal of Drug Issues, 28, 381–394.

16.

Fox

A. D.

Chamberlain

Sohler

N. L.

Frost

Cunningham

C. O.

(2015). Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Journal of Substance Abuse Treatment, 48, 112–116.

17.

Friedmann

P. D.

Lemon

S. C.

Stein

M. D.

D’Aunno

T. A.

(2003). Accessibility of addiction treatment: Results from a national survey of outpatient substance abuse treatment organizations. Health Services Research, 38, 887–903.

18.

Fudala

P. J.

Bridge

T. P.

Herbert

Williford

W. O.

Chiang

C. N.

Jones

… Tusel

(2003). Office-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine, 349, 949–958.

19.

Furst

R. T.

(2013). Suboxone misuse along the opiate maintenance treatment pathway. Journal of Addictive Diseases, 32, 53–67.

20.

Furst

R. T.

(2014). Diffusion and diversion of suboxone: An exploration of illicit street opioid selling. Journal of Addictive Diseases, 33, 177–186.

21.

Genberg

B. L.

Gillespie

Schuster

C. R.

Johansen

C. E.

Astemborski

Kirk

G. D.

Vlahov

Mehta

S. H.

(2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addictive Behaviors, 38(12), 2868–2873.

22.

Huhn

A. S.

Tompkins

D. A.

Dunn

K. E.

(2017). The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug and Alcohol Dependence, 180, 279–285.

23.

Knudsen

H. K.

Lofwall

M. R.

Havens

J. R.

Walsh

S. L.

(2015). States’ implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug and Alcohol Dependence, 157, 36–43.

24.

Kosten

T. R.

George

T. P.

(2002). The neurobiology of opioid dependence: Implications for treatment. Science & Practice Perspectives, 1, 13–20.

25.

Lofwall

M. R.

Havens

J. R.

(2012). Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug and Alcohol Dependence, 126, 379–383.

26.

Lopez

(2019, July 17). New data shows drug overdose deaths fell in 2018: But there’s a big catch. Vox. https://www.vox.com/science-and-health/2019/7/17/20698040/opioid-epidemic-drug-overdose-deaths-2018

27.

Mars

S. G.

Rosenblum

Ciccarone

D. H.

(2019). Fentanyl: The many challenges ahead. Addiction, 114, 785–786.

28.

Mattick

R. P.

Breen

Kimber

Davoli

(2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, 2, Article CD002207.

29.

McLean

Kavanaugh

P. R.

(2019). “They’re making it so hard for people to get help:” Motivations for non-prescribed buprenorphine use in a time of treatment expansion. International Journal of Drug Policy, 71, 118–124.

30.

McLellan

A. T.

Lewis

D. C.

O’Brien

C. P.

Kleber

H. P.

(2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcome evaluations. The Journal of the American Medical Association, 284, 1689–1695.

31.

Metsch

L. R.

McCoy

C. B.

(1999). Drug treatment experiences: Rural and urban comparisons. Substance Use & Misuse, 34, 763–784.

32.

Monte

A. A.

Mandell

Wilford

B. B.

Tenyson

Boyer

E. W.

(2009). Diversion of buprenorphine/naloxone co-formulated tablets in a region with high prescribing prevalence. Journal of Addictive Diseases, 28(3), 226–231.

33.

National Institute on Drug Abuse. (2018). Drugs, brains, and behavior: The science of addiction. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/soa.pdf

34.

Novak

S. P.

Wenger

Lorvick

Kral

(2015). The misuse, abuse and diversion of opioid replacement therapies (ORT): A study of street abusers. Drug and Alcohol Dependence, 146, Article e54.

35.

Patient Protection and Affordable Care Act. (2010). Patient protection and affordable care act, 42 U.S.C. § 18001 §.

36.

Pennsylvania Department of Human Services. (2020a). Estimated number of individuals with drug use disorder year 2016—Current quarterly county & statewide health. https://data.pa.gov/Opioid-Related/Estimated-Number-of-Individuals-with-Drug-Use-Diso/krjw-t48p

37.

Pennsylvania Department of Human Services. (2020b). Individuals with Medical Assistance (MA) receiving Medication-Assisted Treatment (MAT) CY 2015—Current annual county human services. https://data.pa.gov/Opioid-Related/Individuals-with-Medical-Assistance-MA-receiving-M/unzz-dvz6

38.

Peterson

J. A.

Schwartz

R. P.

Mitchell

S. G.

Reisinger

H. S.

Kelly

S. M.

O’Grady

K. E.

… Agar

M. H.

(2010). Why don’t out-of-treatment individuals enter methadone treatment programmes? International Journal of Drug Policy, 21, 36–42.

39.

Redko

Rapp

R. C.

Carlson

R. G.

(2006). Waiting time as a barrier to treatment entry: Perceptions of substance users. Journal of Drug Issues, 36, 831–852.

40.

Rosenblatt

R. A.

Andrilla

C. H. A.

Catlin

Larson

E. H.

(2015). Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Annals of Family Medicine, 13, 23–26.

41.

Schuman-Olivier

Albanese

Nelson

S. E.

Roland

Puopolo

Klinker

Schaffer

H. J.

(2010). Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. Journal of Substance Abuse Treatment, 39(1), 41–50.

42.

Schwartz

R. P.

Gryczynski

O’Grady

K. E.

Sharfstein

J. M.

Warren

Olsen

… Jaffe

J. H.

(2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. American Journal of Public Health, 103, 917–922.

43.

Sigmon

S. C.

(2015). The untapped potential of office-based buprenorphine treatment. The Journal of the American Medical Association Psychiatry, 72, 395–396.

44.

Silverstein

S. M.

Daniulaityte

Martins

S. S.

Miller

S. C.

Carlson

R. G.

(2019). “Everything is not right anymore”: Buprenorphine experiences in an era of illicit fentanyl. International Journal of Drug Policy, 74, 76–83.

45.

Stein

B. D.

Sorbero

Dick

A. W.

Pacula

R. L.

Burns

R. M.

Gordon

A. J.

(2016). Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. The Journal of the American Medical Association, 316, 1211–1212.

46.

Substance Abuse and Mental Health Services Administration. (2019). National Survey of Substance Abuse Treatment Services (N-SSATS): 2018. Data on substance abuse treatment facilities.

47.

Thomas

C. P.

Doyle

Kreiner

P. W.

Jones

C. M.

Dubenitz

Horan

Stein

B. D.

(2017). Prescribing patterns of buprenorphine waivered physicians. Drug and Alcohol Dependence, 181, 213–218.

48.

United States Census Bureau. (n.d.). QuickFacts. https://www.census.gov/quickfacts

49.

U.S. HHS and Substance Abuse and Mental Health Services Administration. (n.d.). Buprenorphine practitioner locater. https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator

50.

Wen

Hockenberry

J. M.

Pollack

H. A.

(2018). Association of buprenorphine-waivered physician supply with buprenorphine treatment use and prescription opioid use in Medicaid enrollees. The Journal of the American Medical Association Network Open, 1, e182943–e182943.

51.

Wenger

L. D.

Rosenbaum

(1994). Drug treatment on demand—Not. Journal of Psychoactive Drugs, 26, 1–11.

52.

Whelan

(2020, January 29). Philly DA Larry Krasner will no longer prosecute people for possession of an addiction treatment drug. The Philadelphia Inquirer. https://www.inquirer.com/health/opioid-addiction/buprenorphine-krasner-district-attorneyphiladelphia-decriminalization-20200129.html

53.

Zule

W. A.

Desmond

D. P.

Vogtsberger

K. N.

(1997). Injecting drug users who want treatment. The American Journal of Drug and Alcohol Abuse, 23, 507–522.